Pharmacotherapeutic group: Genito-urinary system and sex hormones.
Urinary system medication. Other urological preparations.
ATC code: G04BX

ADENOPROSIN (suppositories) is approved and marketed as a medication in the Commonwealth of Independent States (CIS).

The active substance of Adenoprosin is an active complex obtained from the larvae of the insect species Lymantria dispar, which has antioxidant, vasoprotective, anti-inflammatory, and immunomodulatory effects. The biologically active compounds in the preparation reduce the formation of phospholipase A2 and the release of arachidonic acid, leading to a decrease in the synthesis of prostaglandins and leukotrienes (inhibits 5-lipoxygenase). The preparation reduces vascular permeability and prostate edema. The action of Adenoprosin has a beneficial effect in patients with benign prostatic hyperplasia (BPH), including those in whom chronic prostatitis symptoms predominate.

The preparation also regulates the tone and peristalsis of the lower urinary tract segments, making urination more effective by reducing frequency, especially nocturnal urination. Through pathogenetic and non-specific mechanisms, Adenoprosin improves urodynamic parameters and the condition of patients with BPH and chronic prostatitis.

The antioxidant action of Adenoprosin is determined by the water-soluble antioxidant compounds in the preparation and is manifested by the inhibition of lipid peroxidation.

Adenoprosin is recommended in the treatment of benign prostatic hyperplasia (stage I-II), with or without chronic prostatitis. It is also recommended in combination with anti-inflammatory and antimicrobial medications in the treatment of chronic prostatitis.